Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tnsaf who wrote (174)	10/26/1998 10:02:00 AM
From: Russian Bear	Respond to of 1073

Jason, Thanks for the Karnofsky Scale information. It is my understanding that squamous cell carcinoma of the lung is a rather common form of lung cancer (particularly linked to smoking,) accounting for approximately one third of all lung cancer cases (or, possibly 1/3 of NSCLC cases -- I don't remember which.) Additionally, I understand that it tends to be asymptomatic (other than, perhaps, a persistent, dry cough) until the late stages, and so most such patients, I would imagine, should probably score >=90 on the KPS. So, while the amendment to the Phase III protocol is hardly a positive development, I expect that Neu-Sensamide could still retain a claim on a rather robust market, assuming that the newly-narrowed Phase III yields sufficiently encouraging results. Does anyone have reason to disagree with this? (Although, I must agree with Rick -- the mane has to go.) ;-) ............... OXGN's financial data continue to look good to me: - $50 million market cap. - $50 million tax-loss carry-forward. - $33 million (estimate) cash/equivalents currently on the books. The burn rate is not particularly high ($2.8 million, last quarter,) although it will likely accelerate, going forward. Management indicated in the last 10Q that current levels of funding are expected to be sufficient through 12/2000. - OXGNW represent a worst-case dilution of only 8%, and only in the event that OXGN appreciates to over 14 3/8 by the end of 1999. (Because the term of the warrants was already extended once, without a reduction of the exercise price, I am assuming that the exercise price will not be lowered in the future.) ............... Cambretastatin is scheduled to enter the clinic within the next two months. Pre-clinicals were very encouraging. In addition to that press release, here is an interesting abstract (thanks, Dwight Martin, OXGN thread:) ncbi.nlm.nih.gov Thanks and best regards, RB